Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41392-021-00496-5 http://scihub22266oqcxt.onion/10.1038/s41392-021-00496-5 33658482!7925812!33658482     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Signal+Transduct+Target+Ther 2021 ; 6 (1): 107 Nephropedia Template TP {{tp|p=33658482|t=2021. Clinical evidence of an interferon-glucocorticoid therapeutic synergy in COVID-19 |pdf=|usr=}}{{33658482}} gab.com Text Clinical evidence of an interferon-glucocorticoid therapeutic synergy in COVID-19 JO: Signal Transduct Target Ther http://www.kidney.de/pget.php?&tw=1&pmid=33658482 #FOAvip Synthetic glucocorticoid dexamethasone is the first trial-proven drug that reduces COVID-19 mortality by suppressing immune system. In contrast, interferons are a crucial component of host antiviral immunity and can be directly suppressed by glucocorticoids. To investigate whether therapeutic interferons can compensate glucocorticoids-induced loss of antiviral immunity, we retrospectively analyzed a cohort of 387 PCR-confirmed COVID-19 patients with quasi-random exposure to interferons and conditional exposure to glucocorticoids. Among patients receiving glucocorticoids, early interferon therapy was associated with earlier hospital discharge (adjusted HR 1.68, 95% CI 1.19-2.37) and symptom relief (adjusted HR 1.48, 95% CI 1.06-2.08), while these associations were insignificant among glucocorticoids nonusers. Early interferon therapy was also associated with lower prevalence of prolonged viral shedding (adjusted OR 0.24, 95% CI 0.10-0.57) only among glucocorticoids users. Additionally, these associations were glucocorticoid cumulative dose- and timing-dependent. These findings reveal potential therapeutic synergy between interferons and glucocorticoids in COVID-19 that warrants further investigation. Twit Text FOAVip Clinical evidence of an interferon-glucocorticoid therapeutic synergy in COVID-19 ????Signal Transduct Target Ther http://www.kidney.de/pget.php?&tw=1&pmid=33658482 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33658482 #FOAvip English Wikipedia <ref>{{Cite pmid|33658482}}</ref> Clinical evidence of an interferon-glucocorticoid therapeutic synergy in COVID-19 #MMPMID33658482 Lu Y; Liu F; Tong G; Qiu F; Song P; Wang X; Zou X; Wan D; Cui M; Xu Y; Zheng Z; Hong P Signal Transduct Target Ther 2021[Mar]; 6 (1): 107 PMID33658482show ga Synthetic glucocorticoid dexamethasone is the first trial-proven drug that reduces COVID-19 mortality by suppressing immune system. In contrast, interferons are a crucial component of host antiviral immunity and can be directly suppressed by glucocorticoids. To investigate whether therapeutic interferons can compensate glucocorticoids-induced loss of antiviral immunity, we retrospectively analyzed a cohort of 387 PCR-confirmed COVID-19 patients with quasi-random exposure to interferons and conditional exposure to glucocorticoids. Among patients receiving glucocorticoids, early interferon therapy was associated with earlier hospital discharge (adjusted HR 1.68, 95% CI 1.19-2.37) and symptom relief (adjusted HR 1.48, 95% CI 1.06-2.08), while these associations were insignificant among glucocorticoids nonusers. Early interferon therapy was also associated with lower prevalence of prolonged viral shedding (adjusted OR 0.24, 95% CI 0.10-0.57) only among glucocorticoids users. Additionally, these associations were glucocorticoid cumulative dose- and timing-dependent. These findings reveal potential therapeutic synergy between interferons and glucocorticoids in COVID-19 that warrants further investigation. |*COVID-19 Drug Treatment[MESH] |*SARS-CoV-2[MESH] |Adult[MESH] |COVID-19 Nucleic Acid Testing[MESH] |COVID-19/diagnosis/mortality[MESH] |Dexamethasone/*administration & dosage/agonists[MESH] |Drug Synergism[MESH] |Female[MESH] |Humans[MESH] |Interferons/*administration & dosage/agonists[MESH] |Male[MESH] |Middle Aged[MESH]Clinical evidence of an interferon-glucocorticoid therapeutic synergy (epmc).pdf DeepDyve Pubget Overpricing